Third-generation aromatase inhibitors in the treatment of advanced breast cancer

Breast Cancer

Volumn 8, Issue 4, 2001, Pages 305-309

  Nabholtz, Jean Marc A ^a,b   Reese, David M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anastrozole; Aromatase inhibitors; Breast cancer; Exemestane; Letrozole

Indexed keywords

ANASTROZOLE; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; AROMATASE INHIBITOR; EXEMESTANE; LETROZOLE; NITRILE; TAMOXIFEN; TRIAZOLE DERIVATIVE;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; BREAST TUMOR; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; FEMALE; HUMAN; MASTECTOMY; METHODOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME;

ADULT; AGED; ANDROSTADIENES; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MASTECTOMY; MIDDLE AGED; NEOPLASM STAGING; NITRILES; RANDOMIZED CONTROLLED TRIALS; TAMOXIFEN; TREATMENT OUTCOME; TRIAZOLES;

EID: 0035752053     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/BF02967529     Document Type: Conference Paper

References (20)

1. R), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br J Cancer 74:1286-1291, 1996. (Pubitemid 26360121)
2. Dowsett M, Jones A, Johnston SRD, et al: In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer. Clin Cancer Res 1:1511-1515, 1995. (Pubitemid 26028086)
3. Geisler J, King N, Anker G, et al: In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res 4:2089-2093, 1998. (Pubitemid 28415652)
4. banning PE: Pharmacology of new aromatase inhibitors. The Breast 5:202-208, 1996.
5. Jonat W, Howell A, Blomqvist C, et al: A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer 32 A: 404-412, 1996.
6. Buzdar AU, Jones SE, Vogel CL, et al: A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Cancer 79:730-739, 1997. (Pubitemid 27076339)
7. Buzdar AU, Jonat W, Howell A, et al: Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase IE trials. Cancer 83:1142-1152, 1998. (Pubitemid 28419067)
8. Dombernowsky P, Smith I, Falkson G, et al: Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 16:453-461, 1998 (Pubitemid 28135586)
9. Gershanovich M, Chaudri HA, Campos D, et al: Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Ann Oncol 9:639-645, 1998. (Pubitemid 28318197)
10. Buzdar A, Douma J, Davidson N, et al: Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol 19:3357-3366.
11. Kauffman M, Bajetta E, Dirix LY, et al: Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double blind trial. J Clin Oncol 18:1399-1411, 2000. (Pubitemid 30205385)
12. Nabholtz JM, Buzdar A, Pollak M, et al: Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a multicenter North American randomized trial. Arimidex Study Group. J Clin Oncol 18:3758-3767, 2000.
13. Boneterre J, Thurlimann B, Robertson JF, et al: Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 18:3748-3757, 2000.
14. ™) versus tamoxifen as first-line therapy for advanced breast cancer (ABC) in postmenopausal (PM) women - combined analysis from two identically designed multicenter trials. Proc Am Soc Clin Oncol 19:154a, 2000.
15. Mouridsen H, Gershanovich M, Sun Y, et al: Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19:2596-2606, 2001. (Pubitemid 32451796)
16. Paridaens R, Dirix LY, Beex L, et al: Exemestane is active and well-tolerated as first-line hormonal therapy of metastatic breast cancer: results of a randomized phase II trial. Proc Am Soc Clinical Oncol 19:83a, 2000.
17. Lonning PE, Bajetta E, Murraly R, et al: Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J Clin Oncol 18:2234-2244, 2000. (Pubitemid 30350215)
18. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 351:1451-1467, 1998.
19. Hamilton A, Volm M: Nonsteroidal and steroidal aromatase inhibitors in breast cancer. Oncology 15:965-972, 2001. (Pubitemid 33739186)
20. Klijn JGM, Blarney RW, Boccardo F, et al: A new standard treatment for advanced premenopausal breast cancer: a meta-analysis of the Combined Hormonal Agent Trialists' Group (CHAT). Eur J Cancer 34:S90, 1998.